SHIRE PLC
SHIRE PLC (SHPGF): 20 pipeline candidates · ~3 mo cash runway · 19 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.6 months
D/E 0.71 · 0% dilution
Lead: Approved
20 candidates
N/A
N/A
A transparent, data-derived signal for SHIRE PLCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$233.1M
Quarterly Burn
$2.9B
Runway
2.6 mo
Revenue
$3.9B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (20 candidates)
| Drug | Phase |
|---|---|
| adynovi | — |
| antihemophilic factor | Phase 3 |
| askbio009 | Phase 1/Phase 2 |
| atomoxetine | Phase 4 |
| bax 888 | Phase 1/Phase 2 |
| elaprase | Approved |
| elaprase for intravenous infusion | Phase 4 |
| guanfacine | Phase 4 |
| hgt-1110 | Phase 1/Phase 2 |
| iti | Phase 3 |
Showing 10 of 20 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in SHIRE PLC's pipeline?
SHIRE PLC (SHPGF) has 20 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SHIRE PLC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SHIRE PLC has approximately 2.6 months of cash runway.
Get the full picture on SHIRE PLC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.